Cheelcare Inc. is set to report its earnings after the market closes on June 30, 2026. However, investors currently lack key EPS figures to gauge expectations. With a market cap of CA$32.39 million and a history of fluctuating revenues, attention will be on recent growth trends in bookings and product launches.
On June 30, 2026, Cheelcare Inc. will release its earnings for the fiscal period ending April 30, 2026. Although the calendar row lacks EPS figures, recent company developments—including record bookings for its Companion product and the launch of the Curio robotic wheelchair—indicate a pivotal moment for the company. Investors will be eager to see how these factors influence the financial results.
Investor takeaway: Long-term investors should watch for signs of operational stability and growth potential amid ongoing product developments.
Advertisement
Cheelcare Inc.
CHER.V
CHER.V
Cheelcare Inc.
WealthAwesomeMarket cap
$32.39M
52W high
$1.98
52W low
$0.83
1W change
+2.94%
Beta
0.09
Cheelcare's Financial Metrics: A Mixed Picture Ahead of Earnings
Despite a market cap of CA$32.39 million and a TTM EPS of CA$-0.17, Cheelcare's recent growth in bookings and product launches could signal a shift in its financial trajectory. Investors will be looking for clarity on how these developments translate into revenue and profitability in the upcoming earnings report.
Bull case
- Strong Booking Growth: Cheelcare reported a 147% year-over-year increase in Companion product bookings for April 2026, showing strong demand for its offerings.
- New Revenue Streams: The delivery of the Curio robotic wheelchair marks the company's entry into commercial production, which could boost revenue generation moving forward.
- Intellectual Property Strength: The recent patent granted for the Companion platform may strengthen Cheelcare's competitive position in the market.
Bear case
- Negative Profit Margins: With a profit margin of -210.34%, the company faces significant challenges in achieving profitability.
- High Valuation Metrics: The forward P/E ratio of 0x and a high P/B ratio of 100.91x suggest that the stock may be overvalued compared to its current financial performance.
- Market Sensitivity: As a small-cap venture company, Cheelcare may experience higher volatility and sensitivity to market conditions and investor sentiment.
Cheelcare Inc. (CHER.V) Overview
Overview: Cheelcare Inc. specializes in innovative healthcare solutions, particularly focused on assistive technologies for mobility. The company has recently made strides in product development and market penetration. What the screen shows: With a market cap of CA$32.39 million and a TTM EPS of CA$-0.17, Cheelcare's stock has seen a 52-week range from CA$0.83 to CA$1.98. The company is currently navigating a challenging financial landscape with a profit margin of -210.34%. Risks and watch items: Investors should be cautious of the company's high valuation metrics and negative profit margins, which may indicate underlying financial difficulties. Additionally, the volatility typical of small-cap stocks could lead to significant price fluctuations.
Recent Growth in Companion Product Bookings
Overview: Cheelcare reported a remarkable 147% year-over-year increase in Companion product bookings in April 2026, showcasing strong market demand. What the screen shows: This growth trend is significant, especially given the company's previous struggles, and could be a vital indicator of future revenue potential. Risks and watch items: While the increase in bookings is promising, the company must convert these into actual sales and manage production effectively to avoid operational challenges.
Launch of Curio Robotic Wheelchair
Overview: The delivery of Cheelcare's first Curio robotic power wheelchair marks a key milestone in its product lineup, transitioning from development to commercial production. What the screen shows: This product launch could open new revenue streams and enhance the company's market position in the assistive technology sector. Risks and watch items: Investors should monitor the commercial success of the Curio wheelchair and its impact on overall financial performance, especially in light of the company's current profitability challenges.
Advertisement
